{"prompt": "['NET-PRO Protocol v1.3', 'April 2022', '20.', 'Lamarca, A., et al., Follow-Up Recommendations after Curative Resection of Well-Differentiated', 'Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice. J Clin Med, 2019.', '8(10).', '21.', 'Tsoli, M., et al., Current best practice in the management of neuroendocrine tumors. Ther Adv', 'Endocrinol Metab, 2019. 10: p. 2042018818804698.', '22.', 'Stueven, A.K., et al., Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past,', 'Present and Future. Int J Mol Sci, 2019. 20(12).', '23.', 'Dannoon, S.F., S.A. Alenezi, and A.H. Elgazzar, The efficacy of the available peptide receptor', 'radionuclide therapy for neuroendocrine tumors: a meta-analysis. Nucl Med Commun, 2017.', '38(12): p. 1085-1093.', '24.', 'Bodei, L., et al., The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor', 'radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging, 2013.', '40(5): p. 800-16.', '25.', 'Hicks, R.J., et al., ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine', 'Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues.', 'Neuroendocrinology, 2017. 105(3): p. 295-309.', '26.', 'Cuyle, P.J. and H. Prenen, Practical management of toxicities associated with targeted therapies', 'for advanced gastroenteropancreatic neuroendocrine tumors. Ann Gastroenterol, 2018. 31(2):', 'p. 140-150.', '27.', 'Bodei, L., et al., Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours:', 'the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging, 2015. 42(1): p. 5-19.', '28.', 'Harring, T.R., et al., Treatment of liver metastases in patients with neuroendocrine tumors: a', 'comprehensive review. Int J Hepatol, 2011. 2011: p. 154541.', '29.', 'de Hosson, L.D., et al., Clinical benefit of systemic treatment in patients with advanced', 'pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO', 'framework. Ann Oncol, 2017. 28(12): p. 3022-3027.', '30.', 'Ahlstedt, J., et al., Non-Invasive Imaging Methodologies for Assessment of Radiation Damage to', 'Bone Marrow and Kidneys from Peptide Receptor Radionuclide Therapy. Neuroendocrinology,', '2020. 110(1-2): p. 130-138.', '31.', 'Jamar, F., et al., 86Y-DOTAO)-D-Phe1-Tyr3-octreotide (SMT487)-- phase 1 clinical study:', 'pharmacokinetics, biodistribution and renal protective effect of different regimens of amino', 'acid co-infusion. Eur J Nucl Med Mol Imaging, 2003. 30(4): p. 510-8.', '32.', 'Valkema, R., et al., Long-term follow-up of renal function after peptide receptor radiation', 'therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl', 'Med, 2005. 46 Suppl 1: p. 83s-91s.', '33.', 'van der Zwan, W.A., et al., GEPNETs update: Radionuclide therapy in neuroendocrine tumors. Eur', 'J Endocrinol, 2015. 172(1): p. R1-8.', '34.', 'Bodei, L., et al., Long-term evaluation of renal toxicity after peptide receptor radionuclide', 'therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl', 'Med Mol Imaging, 2008. 35(10): p. 1847-56.', '35.', \"O'Dorisio, T.M., A.G. Harris, and M.S. O'Dorisio, Evolution of Neuroendocrine Tumor Therapy.\", 'Surg Oncol Clin N Am, 2020. 29(2): p. 145-163.', '36.', 'Bergsma, H., et al., Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide', 'Therapy with 177)Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with', 'Gastroenteropancreatic Neuroendocrine Tumors. J Nucl Med, 2018. 59(3): p. 452-458.', '37.', 'Goncalves, I., et al., Characteristics and outcomes of therapy-related myeloid neoplasms after', 'peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic', 'neuroendocrine neoplasia: a single-institution series. Eur J Nucl Med Mol Imaging, 2019. 46(9):', 'p. 1902-1910.', '61']['NET-PRO Protocol v1.3', 'April 2022', '38.', 'Bergsma, H., et al., Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate:', 'prognostic factors, incidence and course. Eur J Nucl Med Mol Imaging, 2016. 43(3): p. 453-63.', '39.', 'Riff, B.P., et al., Peptide Receptor Radionuclide Therapy-Induced Hepatotoxicity in Patients With', 'Metastatic Neuroendocrine Tumors. Clin Nucl Med, 2015. 40(11): p. 845-50.', '40.', 'Kaderli, R.M., et al., Therapeutic Options for Neuroendocrine Tumors: A Systematic Review and', 'Network Meta-analysis. JAMA Oncol, 2019. 5(4): p. 480-489.', '41.', 'Sharma, N., et al., Peptide Receptor Radionuclide Therapy Outcomes in a North American', 'Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors. Pancreas, 2017. 46(2): p.', '151-156.', '42.', 'Brighi, N., et al., Therapeutic options in lung neuroendocrine tumors: between established', 'concepts and new hopes. Anticancer Drugs, 2019. 30(7): p. e0784.', '43.', 'Prasad, V., et al., Lessons from a multicentre retrospective study of peptide receptor', 'radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for', 'standardised practice. Eur J Nucl Med Mol Imaging, 2020.', '44.', 'Carnahan, R.M., et al., Exploration of PCORnet Data Resources for Assessing Use of Molecular-', 'Guided Cancer Treatment. JCO Clin Cancer Inform, 2020. 4: p. 724-735.', '45.', \"Pletcher, M.J., C.B. Forrest, and T.W. Carton, PCORnet's Collaborative Research Groups. Patient\", 'Relat Outcome Meas, 2018. 9: p. 91-95.', '46.', 'Ahmad, F.S., et al., Computable Phenotype Implementation for a National, Multicenter', 'Pragmatic Clinical Trial: Lessons Learned From ADAPTABLE. Circ Cardiovasc Qual Outcomes,', '2020. 13(6): p. e006292.', '47.', 'Vinik, E., et al., Development of the Norfolk quality of life tool for assessing patients with', 'neuroendocrine tumors. Pancreas, 2009. 38(3): p. e87-95.', '48.', 'Fortin, M., J. Almirall, and K. Nicholson, Development of a research tool to document self-', 'reported chronic conditions in primary care. J Comorb, 2017. 7(1): p. 117-123.', '49.', \"Weeks, J.C., et al., Relationship between cancer patients' predictions of prognosis and their\", 'treatment preferences. Jama, 1998. 279(21): p. 1709-14.', '50.', 'Hawley, S.T., et al., Decision involvement and receipt of mastectomy among racially and', 'ethnically diverse breast cancer patients. J Natl Cancer Inst, 2009. 01(19) p. 1337-47.', '51.', 'Degner, L.F., J.A. Sloan, and P. Venkatesh, The Control Preferences Scale. Can J Nurs Res, 1997.', '29(3): p. 21-43.', '52.', 'Powe, B.D., Fatalism among elderly African Americans. Effects on colorectal cancer screening.', 'Cancer Nurs, 1995. 18(5): p. 385-92.', '53.', \"Ayanian, J.Z., et al., Patients' experiences with care for lung cancer and colorectal cancer:\", 'findings from the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol,', '2010. 28(27): p. 4154-61.', '54.', 'Cockcroft, D.W. and M.H. Gault, Prediction of creatinine clearance from serum creatinine.', 'Nephron, 1976. 16(1): p. 31-41.', '55.', 'Griffith, S.D., et al., Generating Real-World Tumor Burden Enppoints from Electronic Health', 'Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches', 'for Abstracting Real-World Progression in Non-Small Cell Lung Cancer. Adv Ther, 2019. 36(8): p.', '2122-2136.', '56.', 'Buuren, S.V., Flexible Imputation of Missing Data. 2nd Edition ed. 2018, Boca Raton: CRC Press.', '444.', '57.', 'Gosain, R., et al., Geographic and demographic features of neuroendocrine tumors in the United', 'States of America: A population-based study. Cancer, 2020. 126(4): p. 792-799.', '58.', 'Zornosa, C.C., et al., Baseline demographics of neuroendocrine tumor patients presenting to', 'seven National Comprehensive Cancer Network (NCCN) institutions: Development of a multi-', 'institutional outcomes database. Journal of Clinical Oncology, 2012. 30(15_suppl): p. e14551-', 'e14551.', '62']\n\n###\n\n", "completion": "END"}